linjc16/ctgov huggingface dataset:
Renal Cancer Detection Using Convolutional Neural Networks

Study Overview
=================
Brief Summary
-----------------
We aim to experiment and implement various deep learning architectures in order to achieve human-level accuracy in Computer-aided diagnosis (CAD) systems. In particular, we are interested in detecting renal tumors from CT urography scans in this project. We would like to classify renal tumor to cancer, non cancer, renal cyst I, renal cyst II, renal cyst III and renal cyst VI, with high sensitivity and low false positive rate using various types of convolutional neural networks (CNN). This task can be considered as the first step in building CAD systems for renal cancer diagnosis. Moreover, by automating this task, we can significantly reduce the time for the radiologists to create large-scale labeled datasets of CT-urography scans.

Detailed Description
-----------------
We aim to experiment and implement various deep learning architectures in order to achieve human-level accuracy in Computer-aided diagnosis (CAD) systems. In particular, we are interested in detecting renal tumors from CT urography scans in this project. We would like to classify renal tumor to cancer, non cancer, renal cyst I, renal cyst II, renal cyst III and renal cyst VI, with high sensitivity and low false positive rate using various types of convolutional neural networks (CNN). This task can be considered as the first step in building CAD systems for renal cancer diagnosis. Moreover, by automating this task, we can significantly reduce the time for the radiologists to create large-scale labeled datasets of CT-urography scans.

Official Title
-----------------
Renal Cancer Detection Using Convolutional Neural Networks

Conditions
-----------------
Kidney Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patient with RCC, who underwent surgery Exclusion Criteria: Patients with RCC, who did not underwent surgery
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Renal Cancer<br>Patients identified with RCC | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Predicting recurrences | Predicting recurrences of RCC | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Renal Cancer, Machine Learning
Bioavailability and Metabolism of Voriconazole in Relation to Its Modulation by the CYP2C19 Genetic Polymorphism

Study Overview
=================
Brief Summary
-----------------
The purposes of this study are: To determine the absolute bioavailability of voriconazole after a single oral dose (400 mg voriconazole [VFEND brand]) in comparison to intravenous (i.v.) administration (400 mg VFEND, equivalent to two 10 mg/ml-infusates, each containing 200 mg voriconazole [VRC]) in healthy individuals stratified according to the three predominant CYP2C19 genotypes To investigate the possible pathways of metabolism and their modulation according to genetic polymorphism of CYP2C19 after i.v. and oral administration of VRC.

Detailed Description
-----------------
As CYPs are mainly involved in VRC metabolism it is likely that also gut wall metabolism by CYPs occurs. However, no substantial first pass metabolism of VRC has been reported. In humans the VRC metabolism has not been studied systematically. It is therefore important to assess VRC metabolism on its own and in addition the influence of CYP2C19 genetic polymorphisms on the formation of the different VRC metabolites.

Official Title
-----------------
Bioavailability and Metabolism of Voriconazole as a Function of the CYP2C19 Genotype

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Good state of health (physically and mentally) Exclusion Criteria: Any regular drug treatment within the last two months except for oral contraceptives in female participants Any intake of a substance known to induce or inhibit drug metabolising enzymes or transport system enzymes within a period of less than 10 times the respective elimination half-life Any acute or chronic illness or clinically relevant findings in the pre-study examination Allergies (except for mild forms of hay fever) or history of hypersensitivity reactions Smoking (regular or irregular) Excessive alcohol drinking (more than approximately 30 g alcohol per day) Positive drug screening or known or admitted drug abuse

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
voriconazole, genotype, bioavailability, metabolic clearance
The Effect of 6% Hydroxyethyl Starch 130/0.4 on Blood Loss and Coagulation in Patients Medicated With Antiplatelet Agents Prior to Off-Pump Coronary Bypass Graft Surgery

Study Overview
=================
Brief Summary
-----------------
HES 130/0.4 significantly solution will not affect on coagulation and blood loss in patients medicated with antiplatelet agents prior to off-pump coronary bypass surgery (OPCAB).

Official Title
-----------------
The Effect of 6% Hydroxyethyl Starch 130/0.4 on Blood Loss and Coagulation in Patients Medicated With Antiplatelet Agents Prior to Off-Pump Coronary Bypass Graft Surgery

Conditions
-----------------
Coronary Artery Occlusive Disease

Intervention / Treatment
-----------------
* Drug: 6% hydroxyethyl Stach 130/0.4


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eighty patients undergoing OPCAB, who were exposed to anti platelet agents until 5 days prior to surgery were randomly allocated to infuse HES 130/0.4 up to 30 ml/kg and followed crystalloid infusion or infuse crystalloid only during perioperative period, Exclusion Criteria: Patient who has Valvular disease of heart MI within 3 months,patient under 40% of left ventricle preoperative output left main artery stenosis anemia (hemoglobin < 12 g/dl), coagulopathy (Platelet < 100/nl, activated partial thromboplastin time, aPTT) > 80sec, serum creatinine > 1.2 mg/dl, respiratory disease(asthma, COPD, PaO2 < 70 mmHg, pulmonary hypertension or pulmonary edema, etc) not consented to this trial

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: 6% hydroxyethyl Stach 130/0.4|After dividing patients medicated with HES 130/0.4(maximum 33ml/kg/day) during surgery and one day after from the surgery with patients medicated with crystalloid only, compare the effect on the volume of bleeding, blood transfusion, and blood coagulation when using IV fluid.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TEG, hemoglobin, platelet count, prothrombin time (PT), partial prothrombin time (aPTT), blood loss, amount of transfusion, urine output, comparing the record data of IV fluid consumption |  | Preoperative thromboelastography (TEG) and other coagulation variables were measured and follow up data were collected at immediate postoperatively and 24 hours after surgery. |
Homelessness Prevention: Psychiatric Care With Representative Payeeship

Study Overview
=================
Brief Summary
-----------------
Money management is a neglected issue in maintaining persons with mental illness in the community. This randomized controlled trial (RCT) assessed whether a community-based representative payee program, i.e., money management of Social Security and/or VA benefits, coordinated with VA psychiatric care (CO-RP) could be more effective than customary treatment for veterans who had no representative payee.

Detailed Description
-----------------
Background: Money management is a neglected issue in maintaining persons with mental illness in the community. This randomized controlled trial (RCT) assessed whether a community-based representative payee program, i.e., money management of Social Security and/or VA benefits, coordinated with VA psychiatric care (CO-RP) could be more effective than customary treatment for veterans who had no representative payee. Objectives: After 184 subjects were randomly assigned to CO-RP experimental group or customary care control group, hypotheses were that the CO-RP group would experience: 1) more frequent enrollment in the representative payee program, 2) improved residential status, 3) improved health-related quality of life, including less mental illness symptomatology, 4) less substance abuse, 5) improved money management. Methods: Six-month interviews were completed on 152 of 184 possible subjects (83%) and 12-month interviews were completed on 149 of 184 possible subjects (81%). The six and twelve-month outcomes were analyzed with analysis of covariance using data from the baseline pretest. Status: Completed.

Official Title
-----------------
Homelessness Prevention: Psychiatric Care With Representative Payeeship

Conditions
-----------------
Mental Illness

Intervention / Treatment
-----------------
* Behavioral: Coordinated Representative Payeeship with Case Management


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Severe mental illness; Inability to manage money; VA patient Exclusion Criteria:
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Arm 1<br> | Behavioral: Coordinated Representative Payeeship with Case Management<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Constitution of Cerebrospinal Fluid and Blood Database/Specimen in Acute Stage of Subarachnoid Hemorrhage (aSAH) Patients

Study Overview
=================
Brief Summary
-----------------
Neuropeptide Y (NPY) may play a major role in the pathophysiology of aneurysmal subarachnoid hemorrhage (aSAH). To investigate the correlation of NPY in cerebrospinal fluid (CSF) and blood (serum) and the neurological outcome in the acute stage of aSAH.

Detailed Description
-----------------
Evaluation of Neuropeptides in CSF and serum in SAH patients

Official Title
-----------------
The Possible Role of Neuropeptide Y After Spontaneous Subarachnoid Hemorrhage

Conditions
-----------------
Subarachnoid Hemorrhage

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: spontaneous or aneurysmal subarachnoid hemorrhage Exclusion Criteria: age younger than 18 years or older than 70 years inflammatory disease history of former SAH no ventricular drainage

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| aSAH<br>consecutive patients with spontaneous or aneurysmal subarachnoid hemorrhage | |
| control group<br>no neurological disease but spinal anesthesia | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glasgow Outcome Scale |  | 2011-2016 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
subarachnoid hemorrhage, cerebral vasospasm, neuropeptide Y, spontaneous, aneurysmal
Analysis of Human to Human Transmission of Middle East Respiratory Syndrom Coronavirus (MER-CoV)

Study Overview
=================
Brief Summary
-----------------
This study aimed to analysis the characteristics of MERS transmission and the effect of our institutional personal protective equipment on the controlling the MERS at a tertiary Korean Hospital.

Detailed Description
-----------------
Between May 2015 and Nov 2015, total 186 cases of MERS-Cov infections were reported in South Korea. In June 2015, a female patient visited our emergency department (ED) for care of femur fracture. She was suspected of having MERS-Cov and isolated after 10 hours from the visit of our hospital because her clinical feature was not concordance with typical MERS-Cov infection and she denied the any contact of MERS-Cov patient. Before the transport to the isolation room, she stayed at ED during 8 hours, and admitted the general ward during 2 hours. Approximately 150 including the healthcare providers, patients and laypersons were exposed to the case-patient directly or indirectly. The investigators monitored all possible contacts in the hospital during that time, and analysed the CCTV data of hospital and interviewed all risk-persons. After the hospital outbreak ended, The investigators analysed the data of all behavior and contact history of MERS patient, epidermic and clinical data of infected patients and data of personal protective equipments (PPE) of all exposed persons. Descriptive analysis were conducted for basic epidemiology, transmission rout of MERS in hospital, and the effect of hospital infection control system and PPE of each contacts.

Official Title
-----------------
Analysis of Human to Human Transmission of Middle East Respiratory Syndrom Coronavirus (MER-CoV) and Infection Control Experiences in a Medical Institution of South Korea

Conditions
-----------------
Viral Infection

Intervention / Treatment
-----------------
* Other: Risk of MERS infection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All aged persons who have risk of MERS transmission from a case-patients Exclusion Criteria: No risk of transmission
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| RiskMERS<br>Exposed to case-patients | Other: Risk of MERS infection<br>* HCPs, patients and layperson to closely or indirectly contact a case-patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numbers of infected patient |  | Serologic confimred MERS case within 4 weeks after contacting to a case patients | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MERS-CoV, Infection control, Case-control studies
Conveen Optima Urisheaths With Collecting Bags Versus Absorbents

Study Overview
=================
Brief Summary
-----------------
The objective of this investigation is to asses with validated scales, the impact on the quality of life of men suffering of moderate to severe incontinence of the use of Conveen Optima urisheath in comparison with their usual absorbent protection.

Official Title
-----------------
Evaluation de l'Impact Sur la qualité de Vie de l'Utilisation d'un système Collecteur Conveen( étuis pénien Conveen Optima Avec Poches de Recueil Conveen) Chez Des Hommes Souffrant d'Une Incontinence Urinaire modérée ou sévère, Comparativement à Leur Protection Absorbante Habituelle

Conditions
-----------------
Urinary Incontinence

Intervention / Treatment
-----------------
* Device: Conveen Optima is a urisheath to be used together with a collecting bag for urine
* Device: absorbent protection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient over 18 Out clinic patient Patient using absorbent protection for his urinary incontinence Moderate to severe urinary incontinence (1 hour pad test > 10g) All kind of stable urinary incontinence Patient able to apply himself the device Patient able to understand the questions Patient having given his informed consent Patient whose overall treatment for his urinary incontinence is not modified during the study Exclusion Criteria: Patient having a retracted penis Patient having skin problem on the penis Patient using urisheaths Bedridden patient Institutionalized patient Patient with indwelling catheter or under intermittent catheterisation Patient with fecal incontinence leading to the use of absorbent protection Patient suffering of urinary tract infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Conveen optima urisheaths<br> | Device: Conveen Optima is a urisheath to be used together with a collecting bag for urine<br>* Conveen optima urisheath is intended to be used together with a collecting bag for urine and to be changed on a daily basis<br>|
| Placebo Comparator: absorbent protections<br>The patient use their usual absorbent protection as comparator. All brands are allowed. | Device: absorbent protection<br>* The patient use his usual absorbent protection (same brand), and change it when needed<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact on quality of life |  | Days 0, 15, 30 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy (leakages) |  | days 13, 14, 15 and days 28, 29, 30 |
TVTO Versus TVTFFM for Urinary Stress Incontinence

Study Overview
=================
Brief Summary
-----------------
Women who had urinary stress incontinence and underwent one of two procedures: the classic TVTO or the Folke-Flam method of surgical operation, will be evaluated and compared.

Detailed Description
-----------------
We will enroll women that underwent one of the two surgeries: TVTO or the modification where the needle passes somewhat to the side to prevent the post operative pain, for urinary stress incontinence. Data will be collected from the charts. Telephone interviews will be carried out. Physical examination will also be incorporated.

Conditions
-----------------
Urinary Stress Incontinence Treated by TVT

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with Urinary Stress Incontinence treated by TVT Exclusion Criteria: Women without with Urinary Stress Incontinence or not treated by TVT

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Resolution of urinary stress incontinence | We will question the women as for they have stress urinary incontinence. Physical examination data will also be retrieved. | One year after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Side effect of surgery | We will question the women if they have symptoms such as pain in the hip joints, vaginal discharge and bleeding. Physical examination will be retrieved from the charts. | six-12 months |
Paediatric Subjects - Special Survey

Study Overview
=================
Brief Summary
-----------------
This study is conducted in Japan. The aim of this study is to collect safety and efficacy data when using insulin aspart in children with diabetes under normal clinical practice conditions.

Official Title
-----------------
Special Survey for Paediatric Subjects

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: insulin aspart


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with diabetes requiring insulin therapy Exclusion Criteria: Subjects who had treatment history of insulin aspart

Ages Eligible for Study
-----------------
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Insulin aspart users<br> | Drug: insulin aspart<br>* Prescribed by the physicians as a result of normal clinical practice<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate assessed by the investigator: Ability or failure to achieve expected glycaemic control |  | Year 1 | 
| HbA1c (glycosylated haemoglobin) |  | Year 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hypoglycaemic events |  | Year 1 | 
| Adverse Events |  | Year 1 |